How to Test for Latent Autoimmune Diabetes (LADA)

The central test for latent autoimmune diabetes in adults (LADA) is a blood test measuring antibodies against an enzyme called GAD65, combined with a C-peptide test that gauges how much insulin your pancreas still produces. These two tests, interpreted alongside your clinical picture, form the backbone of LADA diagnosis. But the process is more nuanced than a single blood draw, and understanding which tests to ask for, when they make sense, and what the results actually mean can be the difference between years of wrong treatment and a plan that fits your disease.

The Three Diagnostic Criteria

An international expert panel has established three criteria that define LADA. First, you were diagnosed with diabetes as an adult, typically over age 30. Second, you test positive for at least one diabetes-associated autoantibody. Third, you did not need insulin for at least six months after your initial diagnosis.¹ That last criterion is what separates LADA from classic type 1 diabetes in adults: people with type 1 almost always need insulin right away, while LADA progresses more slowly. If your doctor diagnosed you with type 2 diabetes but you were relatively lean, younger than 50, or found yourself needing insulin sooner than expected, LADA testing is worth discussing.

GAD65 Antibodies Are the Primary Blood Test

Among the various autoantibodies linked to autoimmune diabetes, antibodies to glutamic acid decarboxylase 65 (GAD65, often written as GADA) are considered the most sensitive and specific marker for identifying LADA in people who were initially told they have type 2 diabetes.² This is a straightforward blood test that most endocrinology labs can run. When your doctor orders “GAD antibodies” or “anti-GAD65,” they are looking for immune proteins that target insulin-producing beta cells in your pancreas. A positive result signals that your immune system is attacking those cells, which is the hallmark of autoimmune diabetes rather than insulin-resistance-driven type 2.

Not all positive results carry the same weight, though. GADA titers fall roughly into two categories: high titers (above about 32 arbitrary units in most assays) and low titers. People with high GADA titers look more like classic type 1 diabetes in terms of their immune profile and disease progression, while those with low titers tend to resemble type 2 diabetes more closely in their metabolic features.³ A study from the NIRAD cohort found that about 71% of LADA patients with high GADA titers eventually required insulin, compared with roughly 42% of those with low titers.⁴ So GADA is not just a yes-or-no diagnostic test; the level of antibodies tells your doctor something about how aggressively your disease is likely to progress.

Other Autoantibodies That Add Diagnostic Value

GAD65 antibodies are the workhorse, but they are not the only autoantibodies your doctor might check. Other diabetes-associated antibodies include islet cell antibodies (ICA), antibodies to the tyrosine phosphatase-like protein IA-2, and zinc transporter 8 (ZnT8) antibodies. Testing for multiple antibodies can sharpen the picture considerably. Research has shown that patients positive for both ICA and GAD antibodies, or those with high-titer GADA, tend to have insulin deficiency that resembles type 1 diabetes. By contrast, patients with only a single positive antibody at a low titer often look metabolically more like type 2.⁵

Each additional antibody also carries its own clinical associations. ZnT8 positivity in LADA patients has been linked to lower body weight, female sex, and a shorter disease duration at the time of testing. IA-2 positivity has been associated with lower C-peptide levels, suggesting more advanced beta-cell damage.⁶ In practice, many clinics start with GADA alone and add IA-2 or ZnT8 if the GADA result is borderline or if the clinical suspicion for autoimmune diabetes is strong despite a negative GAD test.

C-Peptide Testing to Measure Remaining Insulin Production

Antibody testing tells you whether autoimmunity is present, but C-peptide testing tells you how much damage has already been done. C-peptide is a byproduct released in equal amounts whenever your pancreas produces insulin, so measuring it gives a reliable snapshot of how much insulin your body is still making on its own.

In classic type 1 diabetes, C-peptide is typically undetectable because beta-cell destruction is nearly complete. In newly diagnosed type 2 diabetes, C-peptide is normal or even elevated because the pancreas is still pumping out insulin to overcome resistance. LADA sits in between: C-peptide is usually low but still detectable at diagnosis, and it tends to decline over time. Multiple studies, including the NIRAD study and the Action LADA cohort, have confirmed that C-peptide levels are significantly lower in LADA than in type 2 diabetes. In fact, finding elevated C-peptide in a patient suspected of having LADA effectively rules it out.⁷

Your doctor may order a fasting C-peptide, a stimulated C-peptide (drawn after a standardized meal), or both. Stimulated values are more informative because they show how well your beta cells respond under demand. Stimulated C-peptide is generally higher in LADA than in classic type 1 at all time points after a meal, which helps distinguish the two conditions.⁷

Why Doctors Should Not Test Everyone

If GADA testing can pick up hidden autoimmune diabetes, why not screen every adult with type 2? The problem is false positives. Autoantibody tests are imperfect, and when you apply an imperfect test to a very large population where most people genuinely have type 2, you end up catching a lot of people whose single positive antibody result does not actually reflect autoimmune disease. In an adult who has no clinical features suggesting autoimmune diabetes, a lone positive antibody is more likely to be a false positive than a true signal of LADA.⁸

This means that testing should be targeted, not universal. The clinical features that should raise a red flag include being diagnosed before age 50, having a body mass index under 25, experiencing unexplained weight loss around diagnosis, reaching a point where oral medications stop controlling blood sugar within a few years, and having a personal or family history of other autoimmune conditions.⁹ If you tick several of those boxes, GADA testing makes sense. If you fit the textbook profile of type 2 diabetes in every way, the odds of a single positive result being meaningful drop substantially.

How Often LADA Gets Misdiagnosed

Estimates suggest that roughly 10% of adults initially diagnosed with type 2 diabetes actually have LADA.¹⁰ Broader estimates for diabetes subtype misclassification put the range at 7 to 15% of all diabetes cases initially receiving the wrong label.¹¹ The consequences are not trivial. Treating LADA as if it were pure type 2 often means relying on medications that push the remaining beta cells harder, like sulfonylureas, which can accelerate their decline rather than preserve them. Misdiagnosis also delays the start of insulin when it is genuinely needed, which can lead to long stretches of poor glucose control and the complications that follow.

The NIRAD study specifically found that sulfonylurea treatment in the first year after a LADA diagnosis was a significant predictor of faster progression to insulin dependence.⁴ Getting the diagnosis right early directly affects which medications make sense and how quickly your doctor should anticipate transitioning to insulin.

Assay Quality and Why the Lab Method Matters

Not all GADA assays are created equal, and the type of lab test used can change your result. The traditional method is the radiobinding assay (RBA), which has been the workhorse of autoantibody testing for decades. A newer technique, the electrochemiluminescence (ECL) assay, appears to be more specific. Research comparing the two has shown that people who test positive for GADA on the older RBA but whose result is not confirmed by ECL tend to have a metabolic profile that looks more like ordinary type 2 diabetes. Their antibodies are lower affinity, which suggests they may not reflect genuine autoimmune beta-cell destruction.¹²

What this means practically is that a positive GADA result on a standard assay, especially at a low titer, is not always a definitive answer. If your result is borderline and your clinical picture is ambiguous, your doctor may want to confirm with a second-generation assay or add other antibody tests and a C-peptide measurement before changing your treatment plan. The field is gradually moving toward ECL-based confirmatory testing, but availability varies by lab.

Autoimmune Conditions as Diagnostic Clues

LADA does not exist in an immune vacuum. People with other autoimmune diseases are at higher risk of developing it, and the association is strong enough to be clinically useful as a screening signal. A large study found that individuals with any autoimmune disease had about 70% higher odds of having LADA compared to the general population. The links were especially pronounced for thyroid disorders, inflammatory bowel disease, and vitiligo, with vitiligo carrying nearly four times the risk.¹³

If you already have Hashimoto’s thyroiditis, Graves’ disease, celiac disease, or vitiligo and you develop diabetes in adulthood, the probability that your diabetes is autoimmune goes up substantially. This is one of the clearest practical applications of the “test selectively, not universally” principle: a personal or family history of autoimmune disease is one of the strongest reasons to pursue GADA testing even when your diabetes otherwise looks like type 2.

Inflammatory Markers Can Help in Ambiguous Cases

When autoantibody results are equivocal, some researchers have explored whether inflammatory markers can help distinguish LADA from both type 1 and type 2. A study measuring several low-grade inflammatory proteins found that certain markers, including soluble TNF receptor II and high-sensitivity CRP, differed between LADA and classic adult-onset type 1 diabetes. A statistical model combining these biomarkers could distinguish the two conditions with reasonable accuracy.¹⁴ These tests are not routine yet, but they illustrate an important point: LADA sits on a spectrum between type 1 and type 2, and sometimes a single autoantibody test is not enough to pin down where on that spectrum a patient falls. In clinical practice, the combination of autoantibodies, C-peptide, and clinical features remains the most reliable approach.

Genetic Testing and HLA Typing

LADA shares some genetic risk factors with type 1 diabetes, particularly in a region of the genome called the HLA complex that governs immune function. Certain HLA haplotypes, especially those involving the DR3 and DR4 gene variants, are well-established risk factors for type 1 diabetes, and many of them also confer risk for LADA. In European populations, the DR3-DQB1*0201 and DR4-DQB1*0302 haplotypes are major susceptibility markers for both conditions, while the DR15-DQB1*0602 haplotype appears strongly protective.¹⁵

However, the genetic overlap is not complete. Research in Chinese populations has shown that the HLA haplotypes most strongly associated with type 1 diabetes do not always carry the same risk for LADA, and some of the highest-risk type 1 genotypes are not associated with LADA at all.¹⁶ This suggests that LADA is not simply “slow type 1” but has its own partially distinct genetic architecture. In practice, HLA typing is rarely used to diagnose LADA. It is expensive, difficult to interpret clinically, and adds little beyond what autoantibody and C-peptide testing already provide. But it does underscore that LADA is a real entity, not just a vague gray zone, and it helps researchers understand why the disease behaves differently from both type 1 and type 2.

Emerging Biomarkers on the Horizon

Researchers are actively hunting for new markers that could improve LADA diagnosis beyond traditional autoantibodies. One promising area involves tiny RNA molecules called microRNAs (miRNAs) carried inside small particles shed by cells into the bloodstream. A recent study identified three specific miRNAs in these blood-borne particles that differed between LADA patients and people with type 2 diabetes. Two of them showed very high diagnostic accuracy in distinguishing the two conditions.¹⁷ This is still early-stage research and not available as a clinical test, but it hints at a future where LADA could be identified through markers that reflect the biological activity of the disease rather than relying solely on autoantibodies that, as noted earlier, have imperfect specificity.

The Cardiovascular Stakes of Correct Diagnosis

Getting the right diagnosis is not just about choosing the right diabetes medication. Data from a large registry covering patients in Germany and Austria found that people with LADA had higher rates of dyslipidemia and high blood pressure than people with either type 1 or type 2 diabetes. After adjusting for age, sex, and how long someone had been living with diabetes, about 91% of LADA patients had dyslipidemia and 78% had hypertension, compared with roughly 82% and 60% for type 2, and 76% and 40% for type 1. Kidney disease was also more common in LADA than in type 1, and peripheral neuropathy rates in LADA exceeded those in both type 1 and type 2.¹⁸

These numbers are striking because LADA patients are sometimes treated as if they simply have a milder form of type 1 once the autoimmune component is recognized. But the cardiovascular risk profile looks, if anything, worse than either type 1 or type 2 in isolation. One possible explanation is that LADA patients carry a combination of autoimmune beta-cell destruction and the metabolic features of insulin resistance, inheriting the worst of both worlds. Whatever the reason, accurate diagnosis means your doctor can screen aggressively for heart disease risk factors, lipid abnormalities, and kidney function rather than assuming the cardiovascular picture will resemble whichever type you were originally thought to have.

A Practical Sequence for Getting Tested

If you suspect LADA, the practical path looks something like this. Start by discussing your clinical profile with your doctor: your age at diagnosis, body weight, how quickly your blood sugar became difficult to manage, and any personal or family history of autoimmune conditions. If these features raise suspicion, the first test to request is GADA. A positive result at a meaningful titer, especially combined with a low or low-normal C-peptide, strongly supports a LADA diagnosis. If GADA is negative but suspicion remains high, testing for IA-2 and ZnT8 antibodies may catch the small fraction of LADA patients who are GADA-negative. A stimulated C-peptide test, where blood is drawn after a standardized meal, provides additional confirmation by showing whether your beta cells are struggling to keep up.

If results are borderline, a second assay method can help clarify whether a low-positive GADA truly reflects autoimmune disease or is a false alarm. Beyond the lab work, your doctor should consider the full clinical context. A single low-titer GADA in someone who is overweight, over 60, and responds well to metformin is a very different finding from the same result in a lean 35-year-old whose blood sugar is climbing despite multiple oral medications. The test results matter, but they only make sense inside the story your body is telling.

1
PubMed Central. Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel
2
PubMed Central. GAD65 autoantibodies and its role as biomarker of Type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA)
3
PubMed Central. Prognosis and outcome of latent autoimmune diabetes in adults: T1DM or T2DM?
4
European Journal of Endocrinology. High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7)
5
PubMed. Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA)
6
PubMed Central. Relationship between β-Cell Autoantibodies and Their Combination with Anthropometric and Metabolic Components and Microvascular Complications in Latent Autoimmune Diabetes in Adults
7
Diabetes & Metabolism Journal. Latent Autoimmune Diabetes in Adults: A Review on Clinical Implications and Management
8
PubMed Central. Latent Autoimmune Diabetes of Adults (LADA) Is Likely to Represent a Mixed Population of Autoimmune (Type 1) and Nonautoimmune (Type 2) Diabetes
9
PubMed Central. Recognizing and Appropriately Treating Latent Autoimmune Diabetes in Adults
10
PubMed Central. Prevalence and factors associated with latent autoimmune diabetes in adults (LADA): a cross-sectional study
11
PubMed Central. Development and Validation of a Prevalence Model for Latent Autoimmune Diabetes in Adults (LADA) Among Patients First Diagnosed with Type 2 Diabetes Mellitus (T2DM)
12
SpringerLink / Diabetologia. Improving clinical utility of GAD65 autoantibodies by electrochemiluminescence assay and clinical phenotype when identifying autoimmune adult-onset diabetes
13
PubMed Central. Autoimmune diseases and the risk and prognosis of latent autoimmune diabetes in adults
14
PubMed. Low-grade Inflammatory Marker Profile May Help to Differentiate Patients With LADA, Classic Adult-Onset Type 1 Diabetes, and Type 2 Diabetes
15
PubMed Central. An association analysis of the HLA gene region in latent autoimmune diabetes in adults
16
The Journal of Clinical Endocrinology & Metabolism. HLA Genetic Discrepancy Between Latent Autoimmune Diabetes in Adults and Type 1 Diabetes: LADA China Study No. 6
17
PubMed. Plasma-derived exosomal miRNAs as potentially novel biomarkers for latent autoimmune diabetes in adults
18
PubMed Central. Increased cardiovascular risk in people with LADA in comparison to type 1 diabetes and type 2 diabetes: Findings from the DPV registry in Germany and Austria